Nonradiolabelled MIBG has recently been suggested as an innovative drug for the treatment of NE gastrointestinal tumours expressing plasma membraneous norepinephrine transporters (NET) (Taal et al, 1996; Höpfner et al, 2002). This evidence concerns the gene SLC6A2 and digestive system neoplasm.